A detailed history of Hantz Financial Services, Inc. transactions in Vaxart, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 7,400 shares of VXRT stock, worth $4,292. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,400
Previous 7,400 -0.0%
Holding current value
$4,292
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$0.53 - $1.3 $3,922 - $9,620
7,400 New
7,400 $5,000
Q2 2022

Aug 06, 2024

BUY
$2.7 - $5.28 $6,210 - $12,144
2,300 Added 45.1%
7,400 $26,000
Q1 2022

Aug 06, 2024

SELL
$4.29 - $6.64 $1,051 - $1,626
-245 Reduced 4.58%
5,100 $26,000
Q1 2021

Aug 06, 2024

SELL
$5.64 - $23.33 $11,590 - $47,943
-2,055 Reduced 27.77%
5,345 $32,000
Q3 2020

Aug 06, 2024

SELL
$4.78 - $16.97 $25,812 - $91,638
-5,400 Reduced 72.97%
2,000 $13,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $73.4M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Hantz Financial Services, Inc. Portfolio

Follow Hantz Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.